Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

SCAI news: Drug-eluting stents prove mettle in heart attack patients

14.07.2005


SCAI is pleased to bring to your attention two important articles published in the just-released issue of Catheterization and Cardiovascular Interventions: Journal of the Society for Cardiovascular Angiography and Interventions (CCI)--



Drug-Eluting Stents Prove Mettle in Heart Attack Patients -- Drug-eluting stents are a safe and effective treatment for heart attack, provoking no increase in complications when compared to conventional stents ... Heart Attack Patients With Blockages in Bypass Grafts Face Poor Outlook -- The outlook is poor for patients who have coronary artery bypass graft surgery and later have a heart attack...

See the text below for details on both articles, or call 717-241-2470 or 717-422-1181 for copies of the articles themselves.


Drug-Eluting Stents Prove Mettle in Heart Attack Patients

Interventional Cardiologists and Patients Can Be Confident in New Treatment Choice

(BETHESDA, MD)--Drug-eluting stents are a safe and effective treatment for heart attack, provoking no increase in complications when compared to conventional stents and cutting the risk of arterial renarrowing by 90 percent. These are the findings of a new study published in the August 2005 issue of Catheterization and Cardiovascular Interventions: Journal of the Society for Cardiovascular Angiography and Interventions.

The study fills an important information gap in the treatment of high-risk patients. Until now, patients with heart attack, or myocardial infarction, have been excluded from studies of drug-eluting stents. Physicians often use drugs and devices that have been approved in one group of patients to extend treatment to a new group of patients, however.

"There is increasing use of drug-eluting stents as the primary treatment for acute myocardial infarction. We wanted to know whether it was safe," said Ron Waksman, M.D., associate director of cardiology at Washington Hospital Center in Washington, D.C.

Drug-eluting stents are expandable metal tubes that prop open an artery supplying blood to the heart while slowly releasing a drug that over time prevents renarrowing, or restenosis. Drug-eluting stents were originally proved safe and effective in patients with simple arterial narrowings causing chest pain, not in patients with heart attack.

The new study involved 103 heart attack patients who were treated with the Cypher stent (Cordis Corp.). This stent is coated with sirolimus, a medication that prevents the overgrowth of scar tissue from the arterial wall into the center of the stent. Patients treated with the Cypher stent were compared to 504 heart attack patients who had been treated with a bare metal stent in the preceding five years.

Dr. Waksman and his colleagues found that treating heart attack patients with the drug-eluting stent was safe. There was no difference between the two groups in procedural complications. Another key finding: No patient developed a blood clot in the drug-eluting stent within a month of treatment, a serious complication known as subacute thrombosis. This is especially reassuring, given that heart attacks are themselves often caused by a blood clot, or thrombus, that blocks the artery following rupture of an inflamed plaque.

"When you have a group of patients who already have a thrombotic milieu, you want to make sure that you’re not risking further thrombosis with the use of drug-eluting stents," Dr. Waksman said.

The study also showed that drug-eluting stents accomplished their primary purpose, preventing the need for a repeat procedure to treat renarrowing in the stented artery. At six-month follow-up, only 1 percent of patients treated with the drug-eluting stent required a new procedure to reopen the artery, as compared to more than 10 percent of patients treated with the bare metal stents.

"Our study reassures interventional cardiologists and patients that we have no reason to worry about using these stents in treating acute myocardial infarction. They appear to be safe--that’s the most important thing--and also effective," Dr. Waksman said.

Dr. Waksman and his colleagues are considering conducting a head-to-head comparison of two types of drug-eluting stents in the treatment of heart attack: the Cypher stent and its competitor, the Taxus stent (Boston Scientific), which is coated with a different anti-renarrowing drug, paclitaxel.

Headquartered in Bethesda, Md., the Society for Cardiovascular Angiography and Interventions is a 3,400-member professional organization representing invasive and interventional cardiologists. SCAI’s mission is to promote excellence in invasive and interventional cardiovascular medicine through physician education and representation, and advancement of quality standards to enhance patient care. SCAI was organized in 1976 under the guidance of Drs. F. Mason Sones and Melvin P. Judkins. The first SCAI Annual Scientific Sessions were held in Chicago in 1978.

To conduct an interview with Dr. Waksman, call 202-877-8575 or send an email to ron.waksman@medstar.net.

The Society for Cardiovascular Angiography and Interventions provides news reports of clinical studies published in Catheterization and Cardiovascular Interventions: Journal of the Society for Cardiovascular Angiography and Interventions (CCI) as a service to physicians, the media, the public, and other interested parties. However, statements or opinions expressed in these reports reflect the view of the author(s) and do not represent official policy of SCAI unless so stated.

Heart Attack Patients With Blockages in Bypass Grafts Face Poor Outlook

Vein-Graft Blockages Signal Severe Disease That Challenges Even Coronary Interventions

(BETHESDA, MD)--The outlook is poor for patients who have coronary artery bypass graft surgery and later have a heart attack caused by blockage of the transplanted vein. Even after receiving the leading treatment for heart attack--a coronary intervention such as angioplasty or stenting--patients with vein grafts face a significantly higher risk of death than do patients whose heart attack resulted from a blockage in a natural coronary artery, according to a study in the August 2005 issue of Catheterization and Cardiovascular Interventions: Journal of the Society for Cardiovascular Angiography and Interventions.

"Even after we fix these grafts, the long-term outlook is still limited. Once patients develop disease in the graft it, tends to progress, and that compromises long-term survival," said Bruce R. Brodie, M.D., who directs the LeBauer Cardiovascular Research Foundation in Greensboro, NC.

Dr. Brodie and his colleagues analyzed data from 2,240 heart attack patients who were treated with a catheter-based coronary intervention such as angioplasty or stenting. Of these, 57 patients had vein-graft blockages and the rest had blockages of a natural coronary artery.

The analysis showed that vein-graft patients were less likely to have brisk blood flow after coronary intervention (81 percent versus 94 percent) and more likely to die while still in the hospital (21 percent versus 8 percent). In addition, after five years, only 56 percent of the vein grafts were still open. After 10 years, fewer than half of vein-graft patients were still alive, as compared to 76 percent of patients whose heart attack was caused by blockage of a natural coronary artery.

Dr. Brodie said that the outlook is getting better, thanks to recent improvements in medications and the introduction of both drug-coated stents and devices to protect against blood clots that break loose during vein-graft procedures. Surgeons are also finding ways to expand the use of arteries rather than veins for bypass surgery. More needs to be done, however.

"We’re treating more and more heart attack patients who have vein-graft blockages," he said. "The bottom line is, we need to look at new and better ways to restore blood flow to the heart in patients with advanced disease."

Headquartered in Bethesda, Md., the Society for Cardiovascular Angiography and Interventions is a 3,400-member professional organization representing invasive and interventional cardiologists. SCAI’s mission is to promote excellence in invasive and interventional cardiovascular medicine through physician education and representation, and advancement of quality standards to enhance patient care. SCAI was organized in 1976 under the guidance of Drs. F. Mason Sones and Melvin P. Judkins. The first SCAI Annual Scientific Sessions were held in Chicago in 1978.

To conduct an interview with Dr. Brodie, call 336-832-8427.

Kathy Boyd David | EurekAlert!
Further information:
http://www.scai.org

More articles from Health and Medicine:

nachricht One gene closer to regenerative therapy for muscular disorders
01.06.2017 | Cincinnati Children's Hospital Medical Center

nachricht The gut microbiota plays a key role in treatment with classic diabetes medication
01.06.2017 | University of Gothenburg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Climate satellite: Tracking methane with robust laser technology

Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.

Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...

Im Focus: How protons move through a fuel cell

Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.

As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...

Im Focus: A unique data centre for cosmological simulations

Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.

With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...

Im Focus: Scientists develop molecular thermometer for contactless measurement using infrared light

Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine

Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...

Im Focus: Optoelectronic Inline Measurement – Accurate to the Nanometer

Germany counts high-precision manufacturing processes among its advantages as a location. It’s not just the aerospace and automotive industries that require almost waste-free, high-precision manufacturing to provide an efficient way of testing the shape and orientation tolerances of products. Since current inline measurement technology not yet provides the required accuracy, the Fraunhofer Institute for Laser Technology ILT is collaborating with four renowned industry partners in the INSPIRE project to develop inline sensors with a new accuracy class. Funded by the German Federal Ministry of Education and Research (BMBF), the project is scheduled to run until the end of 2019.

New Manufacturing Technologies for New Products

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Plants are networkers

19.06.2017 | Event News

Digital Survival Training for Executives

13.06.2017 | Event News

Global Learning Council Summit 2017

13.06.2017 | Event News

 
Latest News

A new technique isolates neuronal activity during memory consolidation

22.06.2017 | Life Sciences

Plant inspiration could lead to flexible electronics

22.06.2017 | Materials Sciences

A rhodium-based catalyst for making organosilicon using less precious metal

22.06.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>